AprilBio Co.,Ltd. Logo

AprilBio Co.,Ltd.

Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.

397030 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
강원도 춘천시 강원대학길 1 의생명과학대학 B동 602호, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AprilBio Co., Ltd. is a clinical-stage biotechnology company that develops innovative biologic drugs. The company's operations are centered on its proprietary SAFA™ (anti-Serum Albumin Fab Associated) platform technology, a long-acting protein engineering solution. The SAFA platform utilizes an albumin binder to extend the half-life of antibody fragments, enhancing their efficacy and safety. AprilBio's research and development pipeline is focused on creating novel therapeutics, branded as SAFAbody™, primarily for the treatment of autoimmune diseases and oncology. The company aims to address unmet medical needs by advancing drug candidates through early clinical development stages for subsequent technology transfer or licensing.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for AprilBio Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Share Issue/Capital Change
전환청구권행사 (제1회차)
Korean 11.8 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.5 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB

Automate Your Workflow. Get a real-time feed of all AprilBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for AprilBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea 229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark NOVO
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.